The FDA has announced two important changes in rapid succession that may represent one of the most consequential shifts in clinical development in decades.

First, the move toward a single pivotal trial (“One Trial”), supported by confirmatory evidence, as the default pathway for late-stage development. Second, and even more transformative, the clear direction toward real-time clinical trials and data-driven regulatory engagement.

Individually, each is meaningful. Together, they redefine how therapies will be developed, evaluated, and delivered.

From Sequential Trials to Continuous Evidence

For decades, clinical development has been structured around phases, pauses, and handoffs. Evidence was generated in steps. Decisions were made after the fact. Regulatory engagement followed documentation, often months removed from the data itself.

The FDA’s recent “One Trial” announcement seeks to compress that model. Now, a single, well-designed pivotal study, supported by appropriate confirmatory evidence and an adequate safety database, can carry the weight of regulatory decision-making in many contexts, reducing unnecessary redundancy, lowering development costs, and accelerating timelines where the evidence is strong enough to support earlier decisions. This is already underway, with a significant portion of recent approvals relying on single pivotal trials, but the FDA’s clarification expands this approach across broader therapeutic areas.

Next, the FDA announced “Real Time Clinical Trials” – a bold move toward a world where clinical evidence is not submitted retrospectively in document form but rather evaluated earlier and more continuously as data. This transition to real-time, event-driven evidence is poised to enable:

• Earlier visibility into safety and efficacy signals for faster regulatory decisions
• Reduced administrative burden and submission overhead
• Earlier and more continuous alignment between sponsors and regulators

Why This Matters

The implications are significant.

Clinical development remains one of the most expensive and time-consuming processes in modern industry. Delays, duplication, and inefficiencies cost the sector tens of billions annually, costs that ultimately propagate to patients and healthcare systems.

By compressing timelines, eliminating redundant trials, and replacing document-heavy workflows with continuous data exchange, this shift has the potential to:

• Dramatically reduce development costs and accelerate timelines
• Improve capital efficiency for sponsors
• Increase the viability of programs in underserved populations
• Accelerate patient access to life-changing therapies

However, this model also raises the bar for sponsors. Real-time regulatory engagement requires continuously updated, analysis-ready data; clear provenance; validation controls; cross-functional alignment across clinical operations, data management, safety, biostatistics, and regulatory; and the ability to explain not only what the data shows, but why it is reliable.

A Moment Worth Recognizing

The FDA is not lowering standards. It is modernizing how evidence is generated and evaluated.

Just as the industry celebrates successful trials and approvals, this moment deserves recognition. The agency is actively reshaping the regulatory paradigm to keep pace with scientific innovation, data complexity, and patient need.

This is the kind of leadership the clinical trial ecosystem requires, and it sets the stage for what comes next: a more continuous, real-time model across clinical development.